Featured News See All November 18, 2024 REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA November 14, 2024 REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 November 6, 2024 REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates Year All202420232022202120202019201820172016201520142013201220112009 Nov 18, 2024 REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA Nov 14, 2024 REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202 Nov 06, 2024 REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates Nov 04, 2024 REGENXBIO to Participate in Upcoming Investor Conferences Oct 30, 2024 REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights Oct 21, 2024 REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024 Oct 18, 2024 REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
Nov 18, 2024 REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
Nov 14, 2024 REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
Oct 30, 2024 REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights
Oct 21, 2024 REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
Oct 18, 2024 REGENXBIO Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
